NCT01589419View on ClinicalTrials.gov

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Locally Advanced Rectal Cancer
Interventions
DRUG

veliparib

see arm description

DRUG

capecitabine

see arm description

RADIATION

radiation

see arm description

Trial Locations (6)

3002

Site Reference ID/Investigator# 67882, East Melbourne

27710

Site Reference ID/Investigator# 68045, Durham

46526

Site Reference ID/Investigator# 112395, Goshen

53792

Site Reference ID/Investigator# 68043, Madison

60611

Site Reference ID/Investigator# 68044, Chicago

85258

Site Reference ID/Investigator# 99095, Scottsdale

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01589419 - A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter